Aktienanalyse zu QuidelOrtho Corp (QDEL)QDELQuidelOrtho Corp

QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Optix and others. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

QuidelOrtho Corp (QDEL) is a good buy right now due to its recent stock surge of 24.61% over the past five days, indicating strong momentum. The current price of $13.42 is significantly below the analyst price target of $18.63, which presents a potential upside of approximately 39%. Additionally, the forward P/E ratio of 9.59 suggests the stock is undervalued relative to its earnings potential. However, investors should be cautious of the company's high debt level, with total debt reaching $2.89 billion, which poses a risk to financial stability.

7 analysts cover QDEL: 5 rate it Buy, 2 Hold and 0 Sell. The average price target is 35.00.